Pfizer may be a bit behind schedule, but it's on track to hack its R&D budget to the $6.5-billion-to-$7-billion target laid out in a radical restructuring plan.
As the pharma industry rethinks the way it brings new drugs to market, drugmakers around the world haven't backed down from their multibillion-dollar research budgets.
This year alone Big Pharma is staring at a loss of patent protection on drugs that bring in $50 billion a year. And the patent cliff has arrived at a time R&D divisions are failing at the task of
Marks & Clerk polled a broad segment of executives in the global biopharma industry and tapped into a strong belief that the pharma industry's looming patent cliff will drive a big round of
Big Pharma companies know all too well that they have a big development problem. As Eli Lilly CEO John Lechleiter has said: "We're taking too long, spending too much and producing far too little.
AstraZeneca faces a critical challenge in gaining new approvals ahead of the patent cliff that's looming for some of its biggest revenue generators. And AZ's business development chief tells
Since Q4 2007, research spending in the U.S. has dropped 4 percent--or $1.9 billion. But report in BusinessWeek today lists 25 major U.S. corporations that, despite the economic downturn, have